89Bio Inc (ETNB)

$10.65 +0.02 (0.19%)
Market Cap 1.55B
Revenue (ttm) 0.00
Net Income (ttm) -367.08M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.06
Volume 955,500
Avg Vol 2,002,920
Day's Range N/A - N/A
Shares Out 145.98M
Stochastic %K 49%
Beta 1.28
Analysts Strong Sell
Price Target $30.70

Company Profile

89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 415 432 9270
Address:
655 Montgomery Street, Suite 1500, San Francisco, United States
sunnykapur
sunnykapur Jul. 14 at 8:12 PM
$ETNB I am bulkish
0 · Reply
JesusIsKing1
JesusIsKing1 Jul. 9 at 6:14 PM
$AIOT Sold $NBIS for a nice profit and started a new position here and also added to my $ETNB position.
0 · Reply
msonfive
msonfive Jul. 8 at 7:48 PM
$ETNB When buyout ?
1 · Reply
Doozio
Doozio Jul. 4 at 4:11 PM
$ETNB a 🧠👀 in da FUTUre of 🧠⏰ INTA and outta 🧠🐑⏰♾️ wen 🌙? 🐒🍌🧠⏰♾️
0 · Reply
BioRich
BioRich Jun. 25 at 4:31 PM
$ALT $ALT Here are the 13 Secondary Endpoints of their MASH P2b trial: 1) Proportion of subjects achieving the composite of both NASH resolution and at least 1 stage improvement of liver fibrosis at 24 weeks [24W] 2) Relative change (%) in liver fat content by MRI-PDFF [Time Frame: 24W/48W] 3) Absolute change in MRI-based corrected T1 (cT1) imaging [24W/48W] 4)Absolute change in alanine aminotransferase (ALT) [24W/48W] 5) Absolute change in Enhanced Liver Fibrosis (ELF) score [24W/48W] 6) Absolute change in Fibroscan-AST (FAST) score [24W/48W] 7) Relative (%) change in body weight [24W/48W] 8) Absolute changes in fasting lipids (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides) [24W/48W] 9) Change in HbA1c (%) [24W/48W] 10) Change in glucose (mg/dL) [24W/48W] 11) Change in systolic and diastolic blood pressure (mmHg) [24W/48W]] 12) Change in heart rate (beats per minute) [24W/48W] 13) Number of subjects with treatment emergent adverse events [48W] $XBI $MDGL $AKRO $ETNB
4 · Reply
hiloSF
hiloSF Jun. 15 at 9:03 PM
$ETNB challenging a major resistance zone 🤼 🚧 👷 👇🏽👇🏿 (Using chart program Pro+ 👉 https://www.tradingview.com/?aff_id=1333 )
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 15 at 8:18 PM
$ETNB With price targets as high as $55 and huge upside potential in MASH and SHTG, 89bio is a high bet on the future of metabolic medicine. https://biotechhealthx.com/biotech-news/89bio-etnb-is-on-every-analysts-watchlist/
0 · Reply
jjmstocks1
jjmstocks1 Jun. 14 at 4:43 PM
$ETNB +30% on the year .. clinical stage biopharma name focused on development/commercialization of therapies .. strong friday session vs the overall market .. finished off with an engulfing bullish candle and was able to get back above the 10-day ..
0 · Reply
jParkz
jParkz Jun. 14 at 10:00 AM
News How To Trade (ETNB) https://marketwirenews.com/news-releases/how-to-trade-etnb--6261819459643179.html $ETNB
0 · Reply
RunnerSignals
RunnerSignals Jun. 13 at 8:23 PM
Solar Squad Heats Up! $RUN and $SEDG lit up the boards $CABA and $ETNB chased the rally and $ARRY slipped into the party late. Who's got the stamina for Monday?
0 · Reply
Latest News on ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 9, 2025, 4:05 PM EDT - 8 days ago

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 4:05 PM EDT - 6 weeks ago

89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

89bio to Participate in Upcoming Investor Conferences

May 6, 2025, 4:05 PM EDT - 2 months ago

89bio to Participate in Upcoming Investor Conferences

89bio Reports First Quarter 2025 Financial Results and Corporate Updates

May 1, 2025, 4:05 PM EDT - 2 months ago

89bio Reports First Quarter 2025 Financial Results and Corporate Updates

89bio: A Buy With Strong Market Opportunity In MASH And SHTG

Apr 18, 2025, 4:46 AM EDT - 3 months ago

89bio: A Buy With Strong Market Opportunity In MASH And SHTG

89bio to Participate in the Leerink Partners Global Healthcare Conference

Mar 3, 2025, 4:05 PM EST - 4 months ago

89bio to Participate in the Leerink Partners Global Healthcare Conference

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Feb 27, 2025, 4:05 PM EST - 5 months ago

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

89bio's Pegozafermin Is Now Gaining Momentum

Jan 30, 2025, 6:05 AM EST - 6 months ago

89bio's Pegozafermin Is Now Gaining Momentum

89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Jan 28, 2025, 10:31 PM EST - 6 months ago

89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Jan 27, 2025, 4:12 PM EST - 6 months ago

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward

Jan 13, 2025, 6:08 PM EST - 6 months ago

89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024

Nov 15, 2024, 8:05 AM EST - 8 months ago

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024

89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 12, 2024, 11:58 PM EST - 8 months ago

89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants

89bio to Participate in the UBS Global Healthcare Conference

Nov 5, 2024, 4:05 PM EST - 9 months ago

89bio to Participate in the UBS Global Healthcare Conference

89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024

Oct 15, 2024, 8:30 AM EDT - 9 months ago

89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024

89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference

Sep 30, 2024, 4:05 PM EDT - 10 months ago

89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference

89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

Sep 16, 2024, 4:05 PM EDT - 10 months ago

89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

89bio: Bullish In Light Of Further MOA Being Established By Peer

Aug 7, 2024, 1:59 PM EDT - 1 year ago

89bio: Bullish In Light Of Further MOA Being Established By Peer

89bio Appoints Francis Sarena as Chief Operating Officer

Aug 7, 2024, 8:00 AM EDT - 1 year ago

89bio Appoints Francis Sarena as Chief Operating Officer

89bio Reports Second Quarter 2024 Financial Results and Corporate Updates

Aug 5, 2024, 4:05 PM EDT - 1 year ago

89bio Reports Second Quarter 2024 Financial Results and Corporate Updates

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

May 23, 2024, 6:32 AM EDT - 1 year ago

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

May 22, 2024, 4:05 PM EDT - 1 year ago

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis

May 14, 2024, 8:00 AM EDT - 1 year ago

89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis

89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 4:05 PM EDT - 1 year ago

89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

89bio to Participate in the BofA Securities 2024 Health Care Conference

May 8, 2024, 4:05 PM EDT - 1 year ago

89bio to Participate in the BofA Securities 2024 Health Care Conference

89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH

May 2, 2024, 4:05 PM EDT - 1 year ago

89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

Apr 17, 2024, 4:05 PM EDT - 1 year ago

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

Mar 27, 2024, 8:00 AM EDT - 1 year ago

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis

Mar 12, 2024, 8:00 AM EDT - 1 year ago

89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 8, 2024, 4:05 PM EST - 1 year ago

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

89bio to Participate in the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 4:05 PM EST - 1 year ago

89bio to Participate in the Leerink Partners Global Biopharma Conference

89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Feb 29, 2024, 4:05 PM EST - 1 year ago

89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 4:05 PM EST - 1 year ago

89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 12, 2023, 7:30 AM EST - 1 year ago

89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Dec 7, 2023, 7:00 AM EST - 1 year ago

89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants

89bio: Despite Peer Trial Setback, Potential Remains In NASH

Dec 6, 2023, 6:59 PM EST - 1 year ago

89bio: Despite Peer Trial Setback, Potential Remains In NASH

89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024

Dec 4, 2023, 7:00 AM EST - 1 year ago

89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024

89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)

Nov 27, 2023, 8:00 AM EST - 1 year ago

89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)

89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference

Nov 21, 2023, 4:01 PM EST - 1 year ago

89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference

89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023

Nov 12, 2023, 12:15 PM EST - 1 year ago

89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023

89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Nov 8, 2023, 4:01 PM EST - 1 year ago

89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

89bio's Low Price Presents An Opportunity

Oct 26, 2023, 2:15 PM EDT - 1 year ago

89bio's Low Price Presents An Opportunity

89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference

Oct 17, 2023, 8:00 AM EDT - 1 year ago

89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference

89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)

Sep 21, 2023, 8:00 AM EDT - 1 year ago

89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)

89bio to Participate in the 2023 Cantor Global Healthcare Conference

Sep 20, 2023, 8:00 AM EDT - 1 year ago

89bio to Participate in the 2023 Cantor Global Healthcare Conference

89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 8:00 AM EDT - 2 years ago

89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

89bio, Inc.: A Big Bet On NASH

Aug 10, 2023, 1:48 PM EDT - 2 years ago

89bio, Inc.: A Big Bet On NASH

89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 9, 2023, 4:01 PM EDT - 2 years ago

89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Weight-loss drugs in development aim to replace injections with pills

Jun 26, 2023, 3:21 PM EDT - 2 years ago

Weight-loss drugs in development aim to replace injections with pills

AKRO LLY MDGL NVO PFE VRTX

89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine

Jun 24, 2023, 5:05 AM EDT - 2 years ago

89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine

sunnykapur
sunnykapur Jul. 14 at 8:12 PM
$ETNB I am bulkish
0 · Reply
JesusIsKing1
JesusIsKing1 Jul. 9 at 6:14 PM
$AIOT Sold $NBIS for a nice profit and started a new position here and also added to my $ETNB position.
0 · Reply
msonfive
msonfive Jul. 8 at 7:48 PM
$ETNB When buyout ?
1 · Reply
Doozio
Doozio Jul. 4 at 4:11 PM
$ETNB a 🧠👀 in da FUTUre of 🧠⏰ INTA and outta 🧠🐑⏰♾️ wen 🌙? 🐒🍌🧠⏰♾️
0 · Reply
BioRich
BioRich Jun. 25 at 4:31 PM
$ALT $ALT Here are the 13 Secondary Endpoints of their MASH P2b trial: 1) Proportion of subjects achieving the composite of both NASH resolution and at least 1 stage improvement of liver fibrosis at 24 weeks [24W] 2) Relative change (%) in liver fat content by MRI-PDFF [Time Frame: 24W/48W] 3) Absolute change in MRI-based corrected T1 (cT1) imaging [24W/48W] 4)Absolute change in alanine aminotransferase (ALT) [24W/48W] 5) Absolute change in Enhanced Liver Fibrosis (ELF) score [24W/48W] 6) Absolute change in Fibroscan-AST (FAST) score [24W/48W] 7) Relative (%) change in body weight [24W/48W] 8) Absolute changes in fasting lipids (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides) [24W/48W] 9) Change in HbA1c (%) [24W/48W] 10) Change in glucose (mg/dL) [24W/48W] 11) Change in systolic and diastolic blood pressure (mmHg) [24W/48W]] 12) Change in heart rate (beats per minute) [24W/48W] 13) Number of subjects with treatment emergent adverse events [48W] $XBI $MDGL $AKRO $ETNB
4 · Reply
hiloSF
hiloSF Jun. 15 at 9:03 PM
$ETNB challenging a major resistance zone 🤼 🚧 👷 👇🏽👇🏿 (Using chart program Pro+ 👉 https://www.tradingview.com/?aff_id=1333 )
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 15 at 8:18 PM
$ETNB With price targets as high as $55 and huge upside potential in MASH and SHTG, 89bio is a high bet on the future of metabolic medicine. https://biotechhealthx.com/biotech-news/89bio-etnb-is-on-every-analysts-watchlist/
0 · Reply
jjmstocks1
jjmstocks1 Jun. 14 at 4:43 PM
$ETNB +30% on the year .. clinical stage biopharma name focused on development/commercialization of therapies .. strong friday session vs the overall market .. finished off with an engulfing bullish candle and was able to get back above the 10-day ..
0 · Reply
jParkz
jParkz Jun. 14 at 10:00 AM
News How To Trade (ETNB) https://marketwirenews.com/news-releases/how-to-trade-etnb--6261819459643179.html $ETNB
0 · Reply
RunnerSignals
RunnerSignals Jun. 13 at 8:23 PM
Solar Squad Heats Up! $RUN and $SEDG lit up the boards $CABA and $ETNB chased the rally and $ARRY slipped into the party late. Who's got the stamina for Monday?
0 · Reply
Market_Max
Market_Max Jun. 13 at 5:39 PM
$SGMT All the folks thinking this is just about Acne....no, it is about the new MoA not just for acne, but for MASH and others. The phase 3 acne data (safety and efficacy) from China all of a sudden validates the MoA as a safe one for MASH, which in turn brings that MoA as an equally viable alternative to TRβ Agonist and FGF21 - bringing all that good efficacy data generated thus far in F2-F3 MASH to the forefront. $AKRO and $ETNB have huge market valuations...a comparable number in Mcap for SGMT will take this to well over $25 right now. This has room to move up still.
0 · Reply
TegridyStocks
TegridyStocks Jun. 10 at 9:58 AM
$ETNB bullish over $10.66
0 · Reply
LewisDaKat
LewisDaKat Jun. 1 at 9:56 PM
$ETNB News $ETNB (ETNB) Long Term Investment Analysishttps://marketwirenews.com/news-releases/-etnb-long-term-investment-analysis-8203018858309358.html
0 · Reply
SYC80
SYC80 May. 30 at 7:15 PM
$ETNB finally over 10
0 · Reply
vu_jade
vu_jade May. 29 at 7:15 PM
$ETNB potential
0 · Reply
JesusIsKing1
JesusIsKing1 May. 27 at 3:22 PM
$ETNB Added. I can see big gains coming here soon.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed May. 22 at 4:11 PM
$MDGL we go green on the backs of $AKRO and $ETNB buyout.
0 · Reply
GreenEnergy2022
GreenEnergy2022 May. 22 at 12:29 PM
$ALT $MDGL Huge rally on 350% on their MASH data, ALT will release MASH data by end of June. And have the potential to be first & best in class at 24w $AKRO $ETNB
1 · Reply
ObeCalp
ObeCalp May. 21 at 7:50 PM
$ETNB is like alligator in a pond... I really want to touch but... not a good idea
1 · Reply
vu_jade
vu_jade May. 21 at 7:09 PM
$ETNB very interesting
0 · Reply
GSP
GSP May. 21 at 12:34 PM
$APLD $ASST $ETNB $CART $WRBY
0 · Reply
valueforme
valueforme May. 20 at 11:13 PM
Afrer Madrigal showed via their sales trajectory that MASH market is real, fhings started to move. FGF-21s are being the focus so far: Boston acquired, $AKRO - rumors, $ETNB - follower. Novo will file sNDA for semaglutide in MASH in the coming months. So, we'll likely end up in a multi combo setup by 2030: - oral combos (Madrigal's resmetirom+ Denifanstat $SGMT is most probable, can be resmetirom+ lanifibranor) - injectable combos: GLP1 + FGF21 (Novo / Lilly) or RNA silencing+ FGF21 (GSK)
1 · Reply